Cerebral Vascular Toxicity of Antiretroviral Therapy.
Luc BertrandMartina VelichkovskaMichał ToborekPublished in: Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology (2019)
HIV infection is associated with comorbidities that are likely to be driven not only by HIV itself, but also by the toxicity of long-term use of antiretroviral therapy (ART). Indeed, increasing evidence demonstrates that the antiretroviral drugs used for HIV treatment have toxic effects resulting in various cellular and tissue pathologies. The blood-brain barrier (BBB) is a modulated anatomophysiological interface which separates and controls substance exchange between the blood and the brain parenchyma; therefore, it is particularly exposed to ART-induced toxicity. Balancing the health risks and gains of ART has to be considered in order to maximize the positive effects of therapy. The current review discusses the cerebrovascular toxicity of ART, with the focus on mitochondrial dysfunction. Graphical Abstract Graphical representation of the interactions between HIV, antiretroviral therapy (ART), and the blood-brain barrier (BBB).
Keyphrases
- antiretroviral therapy
- hiv infected
- hiv positive
- human immunodeficiency virus
- hiv infected patients
- hiv aids
- oxidative stress
- blood brain barrier
- stem cells
- oxide nanoparticles
- multiple sclerosis
- diabetic rats
- mesenchymal stem cells
- white matter
- bone marrow
- subarachnoid hemorrhage
- cerebral ischemia
- endothelial cells
- south africa